Sign inCreate account

Report workspace tools

NCT03796884ACTIVE_NOT_RECRUITINGanonymous

Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer

Sponsor

Source record

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Guanylate cyclase C (GUCY2C) receptor

Indication / condition

AI-normalized

Colorectal Adenoma

Intervention

Source record

Linaclotide, Placebo

Source & freshness

Source record

NCT ID

NCT03796884

Original source

ClinicalTrials.gov

Source last updated

Apr 02, 2026

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03796884

Title

Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Condition raw

Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8

Condition normalized

Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Guanylate cyclase C (GUCY2C) receptor

Target normalized

Guanylate cyclase C (GUCY2C) receptor

Interventions

Linaclotide, Placebo

Public preview

Source record

Linaclotide, a small protein targeting the GUCY2C receptor, is being evaluated for its efficacy in patients with stages 0-3 colorectal cancer and sporadic colorectal adenomas. The trial is sponsored by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and is currently active but not recruiting. The market for colorectal cancer therapies is significant, with increasing demand for innovative treatments that can improve patient outcomes. If successful, linaclotide could enhance the therapeutic landscape for colorectal cancer, particularly in early-stage disease, potentially positioning it favorably against existing therapies. The collaboration with the U.S. Department of Defense may also provide additional funding and support for further development. Diligence should focus on the competitive landscape, particularly other agents targeting GUCY2C and their clinical progress.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03796884

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Executive brief

Investment-Ready Snapshot

Linaclotide, a small protein targeting the GUCY2C receptor, is being evaluated for its efficacy in patients with stages 0-3 colorectal cancer and sporadic colorectal adenomas. The trial is sponsored by the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and is currently active but not recruiting. The market for colorectal cancer therapies is significant, with increasing demand for innovative treatments that can improve patient outcomes. If successful, linaclotide could enhance the therapeutic landscape for colorectal cancer, particularly in early-stage disease, potentially positioning it favorably against existing therapies. The collaboration with the U.S. Department of Defense may also provide additional funding and support for further development. Diligence should focus on the competitive landscape, particularly other agents targeting GUCY2C and their clinical progress.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 02, 2026
Internal syncJun 12, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03796884

Indication

Colorectal Adenoma

Modality

small molecule

Target

Guanylate cyclase C (GUCY2C) receptor

Intervention

Linaclotide, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.